Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study-Reference-Cited by-同舟云学术

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

Published:2020-07-30 Issue:5 Volume:192 Page:869-878
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Chari Ajai¹^ORCID,Rodriguez‐Otero Paula²,McCarthy Helen³,Suzuki Kenshi⁴,Hungria Vania⁵,Sureda Balari Anna⁶^ORCID,Perrot Aurore⁷,Hulin Cyrille⁸,Magen Hila⁹^ORCID,Iida Shinsuke¹⁰,Maisnar Vladimir¹¹,Karlin Lionel¹²,Pour Ludek¹³,Parasrampuria Dolly A.¹⁴^ORCID,Masterson Tara¹⁴,Kosh Michele¹⁴,Yang Shiyi¹⁴,Delioukina Maria¹⁴,Qi Ming¹⁴,Carson Robin¹⁴,Touzeau Cyrille¹⁵^ORCID

Affiliation:

1. Icahn School of Medicine at Mount Sinai New York NY USA

2. Clínica Universidad de Navarra‐CIMAIDISNA, CIBERONC Pamplona Spain

3. Royal Bournemouth Hospital Bournemouth UK

4. Department of Hematology Japanese Red Cross Medical Center Tokyo Japan

5. Clinica Medica São Germano São Paulo Brazil

6. Hematology Department Institut Català d'Oncologia – HospitaletIDIBELLUniversity of Barcelona Barcelona Spain

7. CHU de ToulouseIUCT‐OUniversité de ToulouseUPSService d'Hématologie Toulouse France

8. Department of Hematology Hôpital Haut LévêqueUniversity Hospital Pessac France

9. Department of Hematology Chaim Sheba Medical Center Ramat‐Gan, Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

10. Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan

11. 4th Department of Medicine – Haematology Charles University Hospital Hradec Králové Czech Republic

12. Department of Hematology Centre Hospitalier Lyon SudHospices Civils de Lyon Pierre‐Bénite France

13. University Hospital Brno Brno Czech Republic

14. Janssen Research & Development, LLC Spring House PA USA

15. Hematology Department University Hospital Hôtel‐Dieu Nantes France

Funder

Janssen Research and Development, LLC

Janssen Global Services, LLC

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16980

Reference24 articles.

1. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

2. The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking

3. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

4. Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

5. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA;American Journal of Hematology;2024-01-31

2. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma;New England Journal of Medicine;2024-01-25

3. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review;Frontiers in Oncology;2024-01-25

4. Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias – A Single Centre Experience.;Clinical Hematology International;2024-01-16

5. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database;Expert Opinion on Drug Safety;2023-12-18